nOink and MKD
nOink have created and released the world’s first MKD (Mevalonate Kinase Deficiency) app.
nOink, a UK based software company who’s platform allows users to track and manage any medical condition released the app recently. By creating this, nOink now offers, for the first time, a way for MKD patients to record and monitor their illness in a consistent fashion. You can sign up HERE
"The way technology has been creating health apps is far too silo’d and fragmented" says nOink Co-founder Trevor Gill.
nOink are creating a platform to manage ANY medical condition and MKD is the first example of the use of this platform to meet the need of often under-represented conditions.
"An ’APP’ is probably a misnomer for what we are doing with nOink" says nOink co-founder Dr Liam Holohan. HealthTech is rife with single condition apps that only serve to fragment patient data further. Single condition is not the reality for patients and most systems completely fail to address the co-morbidity reality that families face.
"At nOink we prefer to call what create a ’Condition pack’ " continues Dr Holohan. We talk to Patients, clinicians and other experts and create a pack that is simply installed onto the platform. You can have as many conditions or family members as you like on our system.
nOink is starting with the philosophy of multi-user (think family), multi-condition and multilingual to produce the next generation of personal health management technology.
Rare diseases by their nature are not economically viable for traditional software development methods. If a rare disease app gets created at all it is usually by a charity or Philanthropist and its reach is therefore limited and its focus too narrow.
To put it in the context of drug discovery Dr Holohan says "Rare diseases may rely on orphan drugs but should not have to rely on orphan apps" .
By creating a platform that you configure rather than code means you can address the needs of any condition, no matter how rare.
To proving their philosophy, nOink worked with a expert patient group and created within a matter of weeks, not only the first, but also a comprehensive tool for MKD patients everywhere.
Another benefit of the platform is its real-time multilingual nature whereby you can record notes in one language and others such as your doctors can see your data in another language. Having a rare condition is bad enough but we do not want language to add a further barrier to getting the best healthcare possible.
BACK TO NEWS